Perspective: Multimodality Radionuclide Therapy of Progressive Disseminated Lymphoma and Neuroendocrine Tumors as a Paradigm for Cancer Control
- 1 November 2012
- journal article
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 27 (9) , 525-529
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Progression-Free Survival: Meaningful or Simply Measurable?Journal of Clinical Oncology, 2012
- Radiologic Reviews: More Second Guessing From Armchairs Cannot Lead the WayJournal of Clinical Oncology, 2012
- Time To Remember To Forget Dose-Intensification in LymphomaJournal of Clinical Oncology, 2011
- Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patientsBlood, 2011
- Impact of Rituximab Treatment on90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin LymphomaJournal of Nuclear Medicine, 2009
- Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapyBlood, 2009
- Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular LymphomaJournal of Clinical Oncology, 2008
- Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood, 2005
- Pretreatment with Rituximab Enhances Radiosensitivity of Non-Hodgkin's Lymphoma CellsJournal of Radiation Research, 2005
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998